Fisiopatología y características clínicas | 06 AGO 03

Complicaciones a largo plazo del síndrome urémico hemolítico

Las características clínicas clásicas del SUH incluyen la tríada de anemia hemolítica microangiopática, trombocitopenia e insuficiencia renal aguda.
Autor: Dra. Sharon P. Andreoli* Fuente: Department of Pediatrics and the Herman B. Wells Center for Pediatric Research. Indiana University School of Medicine, Indianapolis, IN, USA. Arch.Latin.Nefr.Ped. 2003; 3(1)

1 . Repetto HA. Epidemic hemolytic uremic syndrome in children. Kidney Int 1997; 52:1708-1719.
2 . Boyce TG, Swerdlow DL, Griffin PM. Escherichia coli 0157:H7 and the hemolytic-uremic syndrome. N EngJ Med 1995; 33:364-368.
3 . Su C, Brandt LJ. Escherichia coli 0157:H7 infection in humans. Ann Intern Med 1995; 123:698-714.
4 . Rowe PC, Orrbine E, Wells GA, Yetisir E, Clulow M, McLaine PN. Risk of hemolytic uremic syndrome aftersporadic Escherichia coli 0157:H7 infection: Results of a Canadian collaborative study. J Pediatr 1998;132 :777 - 782
.5 . Warwicker P, Goodship TJH, Donne RL, Pirson Y, Nicholls A, Ward RM, Turnpenny P, Goodship JA.Genetic studies into inherited and sporadic hemolytic syndrome. Kidney Int 1998; 53:836-844.
6 . Kaplan BS, Meyers KE, Schulman SL. The pathogenesis and treatment of the hemolytic uremic syndrome.Journal of the American Society of Nephrology 1998;9:1126-1133, .
7 . Brandt JR, Fouser LS, Watkins SL, Zelikovic I, Tarr PI, Nazar-Stewart V, Avner ED. Escherichia coli 0157:H7- associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. J Pediatr 1994; 125:519-526.
8 . Yamasaki S, Takeda Y. Enterohemorrhagic Escherichia coli O157:H7 episode in Japan with a perspective on vero toxins (shiga-like toxins). J Toxicol-Toxin Reviews 1997; 16:229-240
9 . Cody SH, Glynn K, Farrar JA, Cairns KL, Griffin PM, Kobayashi J, Fyfe M, Hoffman R, Ling AS, Lewis JH, Swainathin B, Bruant RG, Vugia DJ. An outbreak of
Escherichia coli O157:H7 infection from unpasteurized commercial apple juice. Annals of Int Med 1999; 130 : 202 -209 .
1 0 . Parry SM, Salmon RL, Willshaw GA, Cheasty T. Risk factors for and prevention of sporadic infectious with verocytotoxin (shiga toxin) producing Escherichia coli 0157. Lancet 1998, 351:1019-1022.
11 . Voss E, Paton AW, Manning PA, Paton JC. Molecular analysis of shiga toxigenic Escherichia coli 0111:Hproteins which react with sera from patients with
hemolytic uremic syndrome. Infection and Immunity 1998; 66:1467-1472.
12 . Henning PH, Tham ECB, Martin AA, Beare TH, Jureidinid KF. Hemolytic-uremic syndrome outbreak caused by Escherichia coli 0111:H -: clinical outcomes.
Medical Journal Australia 1998; 168:552-555.
13 . Hashimoto H, Mizukoshi K, Nishi M, Kawakita T, Hasui S, Kato Y, Ueno Y, Takeya R, Okuda N, Takeda T. Epidemic of gastrointestinal tract infection including
hemorrhagic colitis attributing to shiga toxin 1-producing Escherichia coli 0118:H2 at a junior high school in Japan. Pediatr 1999; 103:e2.
14 . Bell BP, Griffin PM, Lozano P, Christie DL, Kobayashi JM, Tarr PI. Predictors of hemolytic uremic syndrome in children during a larger outbreak of Escherichia
coli O157:H7 infections. Pediatrics 1997; 100:e12.
15 . Andreoli SP, Bergstein JM. Development of insulin dependent diabetes mellitus during the hemolytic uremic syndrome. Journal of Pediatrics 1982;
100 : 541 - 545 .
16 . Andreoli SP, Bergstein JM. Acute rhabdomyolysis associated with the hemolytic-uremic syndrome. Journal of Pediatrics 1983; 103:78-80.
17 . Inward CD, Howie AJ, Fitzpatrick MM, Rafaat F, Milford DV, Taylor CM. Renal histopathology in fatal cases of diarrhea associated hemolytic uremic syndrome. Pediatr Nephrol 1997; 11:556-559.
18 . van Setten PA, van Hinsbergh VWM, van den Heuvel LPWJ, Preyers F, Dijkman HBPM, Assmann KJM, van der Velden TJAM, Monnens LAH. Monocytes chemoattractant protein-1 and interleukin-8 levels in urine and serum of patients with hemolytic uremic syndrome. Pediatr Res 1998; 43:759-767.
19 . Moghal NE, Ferreira MAS, Howie AJ, Milford DV, Raafat F, Taylor CM. The late histologic finding in diarrhea associated hemolytic uremic syndrome. J
Pediatr 1998; 133:220-223.
20 . Caletti MG, Gallo G, Gianantonio CA. Development of focal segmental sclerosis and hyalinosis in hemolytic uremic syndrome. Pediatr Nephrol 1996; 10:687-692.
21 . Andreoli SP, Bergstein JM. Exocrine and endocrine pancreatic insufficiency and calcinosis following the hemolytic uremic syndrome. Journal of Pediatrics
1987; 110: 816-817.
22 . Andreoli SP. Pancreatic involvement in the hemolytic uremic syndrome. En: Kaplan BS, Trompeter R, Moak J., eds. The hemolytic uremic syndrome: Thrombotic thrombocytopenia purpura. New York: Markel Dekkar Inc 1992; 131-141.
23. Turfo A, Arrizurieta EE, Repetto H. Renal functional reserve in children with a previous episode of HUS. Pediatric Nephrology 1991; 5:184-188.
24 . Siegler RL, Milligan MK, Burningham TH, Christofferson RD, Chang SY, Jorde LB. Long-term outcome and prognostic indicator in the hemolytic uremic syndrome.
J Pediatr 1991; 118:195-200 .
25 . Gaganadoux MF, Habib R, Gubler MC, Bacri LJ, Broyer M. Long-term (15-25 years) outcome of childhood hemolytic-uremic syndrome. Clinical Nephrology
1996; 46:39-41.
26 . Perlstein EM, Grunfeld BG, Simsolo RB, Gimenez, Gianantonio CA. Renal functional reserve compared in hemolytic uraemic syndrome and single kidney.
Arch Dis Child 1991; 65:728-731.
27 . Spizzirri FD et al. Childhood hemolytic uremic syndrome in Argentina: long-term follow up and prognostic features. Pediatric Nephrology 1997;
11 : 156 - 160 .
28 . Keusch GT, Acheson DWK. Thrombotic thrombocytopenia purpura associated with shiga toxins. Seminars in Hematology 1997; 34:106-116.
29 . Paton JC, Paton AW. Pathogenesis and diagnosis of shiga toxin-producing Escherichia coli infections. Clinical Microbiology Reviews 1998; 11:450-479.
30 . Acheson DWK, Moore R, DeBreuler S. Translocation of Shiga-like toxins across polarized intestinal cells in tissue culture. Infect Immun 1996; 64:3294-3300.
31 . Uchida H, Kiyokawa N, Horie H, Fujimoto J, Takeda T. The detection of Shiga toxins in the kidney of a patient with hemolytic uremic syndrome. Pediatr Res 1999;
45 : 133 - 137 .
32 . van Setten PA, van Hinsbergh VWM, van der Velden TJAN, van de Kar NCAJ, Vermeer M, Mahan JD, Assmann KJM, van den Heuvel LPWJ, Monnens LAH. Effects of TNFa on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. Kidney Int 1997; 51:1245-1256.
33 . Kiarash A, Boyd B, Lingwood CA. Glycosphingolipid receptor function is modified by fatty acid content. J Biol Chem 1994; 269:1138-1146.
34 . Sandvig K, Garred O, van Helvoort A, van Meer G, van Deurs B. Important of glycolipid synthesis for butyric acid induced sensitization to shiga toxin and intracellular sorting of toxin in A431 cells. Molecular Biology of the Cell 1996; 7:1391-1404.
35 . Arab S, Lingwood CA. Intracellular targeting of the Arch.Latin.Nefr.Ped. 2003; 3(1) endoplasmic reticulum/nuclear envelope by retrograde transport may determine cell hypersensitivity to verotoxin via globotriosyl ceramide fatty acid isoform traffic. J Cell Physiol 1998, 117:646-660.
36 . Bitzan MM, Wang Y, Lin J, Marsden PA. Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS)
expression and NO production in vascular endothelium. J Clin Invest 1998; 101:372-382.
37 . Andreoli SP, Green DF. Verotoxin promotes nitric oxide generation in glomerular endothelial cells (GEC) and accelerates PMN mediated GEC injury. J Am Soc Nephrol 1997; 8:582A.
38 . Simon M, Learly TG, Hernandez JD, Abboud HA. Shiga toxin 1 elicits diverse biological response in mesangial cells. Kidney Int 1998; 54:1117-1127.
39 . Van Setten PA, Van Hinsbergh VWM, Van den Heuvel LPWJ, Van der Velden TJAN, Van de Kar NCAJ, Krebbbers RJM, Karmali MA, Monnen LAH. Verocytotoxin inhibits mitogenesis and protein synthesis in purified human glomerular mesangial cells without affecting cell viability: evidence for two
distinct mechanisms. J Am Soc Nephrol 1997;8:1877- 1888 .
40 . Hughes AK, Sticklett PK, Kohan DE. Cytotoxic effect of shiga toxin-1 on human proximal tubular epithelial cells. Kidney Int 1998; 54:426-437.
41 . Hughes AK, Stricklett PK, Kohan DE. Shiga toxin-1 regulation of cytokine production by human proximal tubule cells. Kidney Int 1998;54:1093-1106.
4 2 . Taghchi T, Uchida H, Kiyokawa N, Mori T, Sato N, Horie H, Takeda T, Fujimoto J. Verotoxins induce apoptosis in human renal tubular epithelium derived
cells. Kidney Int 1998; 53:1681-1688.
43 . Karpman D, Hakansson A, Perez MT, Isaksson C, Carlemalm E, Caprioli A, Svanborg C. Apoptosis of renal cortical cells in the hemolytic uremic syndrome:
in vivo and in vitro studies. Infect & Immunity 1998; 66 : 636 - 644 .
44 . Fitzpatrick MM, Shah V, Trompeter RS, Dillon MJ, Barratt TM. Interleukin-8 and polymorphonuclear leucocyte activation in hemolytic uremic syndrome of childhood. Kidney Int 1992; 42:951-956.
45 . Walters MDS, Matthei IU, Kay R, Dillon MJ, Barratt TM. The polymorphonuclear leucocyte count in childhood
hemolytic uraemic syndrome. Pediatr Nephrol 1989; 3:130-134.
46 . Morigi M, Micheletti G, Figliuzzi M, Imberti B, Karmali MA, Remuzzi A, Remuzzi G, Zoja C. Verotoxin-1 promotes leukocyte adhesion to cultured endothelial cells under physiologic flow conditions. Blood 1995; 86 : 4553 - 4558 .
47 . Harel Y, Silva M, Giroir B, Weinberg A, Clearly TB, Beutler B. A reporter transgene indicates renal specific induction of tumor necrosis factor (TNF) by shiga-like toxin. J Clin Invest 1993; 92:2110-2116.
48 . Yuhas H, Kaminsky E, Mor M, Ashkenazi S. Induction of nitric oxide production in mouse macrophages by shiga toxin. J Med Microbiol 1996; 45:97-102.
49 . Inward CD, Varagunam M, Milford DV, Taylor CM. Cytokines in hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli
infection. Archiv Dis Child 1997; 77:145-147.


Usted debe estar registrado para expresar su opinión. Si ya es usuario de IntraMed o desea registrase como nuevo usuario, ingrese aquí
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2017